drugset / Trial / NCT06152809
CIML NK Cells With Venetoclax for AML
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this research study is to test the safety and to explore the effectiveness of infusing cytokine- induced memory-like (CIML) natural killer (NK) cells in combination with Interleukin-2 (IL-2) and standard-of-care venetoclax as a treatment for Acute Myeloid Leukemia (AML). Names of the study therapies involved in this study are: * Lymphodepleting therapy with Fludarabine and Cyclophosphamide prior to CIML NK cell infusion * CIML NK (a cellular therapy) * IL-2 (a recombinant, human glycoprotein) * Venetoclax (a selective inhibitor of BCL-2 protein)
Timeline
- Start
- 2024-02-20
- Primary completion
- 2026-11-30
- Completion
- 2027-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CIML-NK Cells | Cell therapy | — | Intravenous |
| Background | Venetoclax | Small molecule | — | Oral |
| Background | aldesleukin | Protein / enzyme biologic | 2.2e+07 iu | Subcutaneous |